Related Experiment Video

Updated: Jun 3, 2025

A Cell Culture Model for Studying the Role of Neuron-Glia Interactions in Ischemia
11:36

A Cell Culture Model for Studying the Role of Neuron-Glia Interactions in Ischemia

Published on: November 14, 2020

9.3K

The Neuroprotective Role of A2A Adenosine Purinoceptor Modulation as a Strategy Against Glioblastoma

Júlia Leão Batista Simões1, Geórgia de Carvalho Braga1, Michelli Fontana1

  • 1Medical School, Federal University of Fronteira Sul, Chapecó 89815-899, SC, Brazil.

Brain Sciences
|January 8, 2025
PubMed

Insights

Glioblastoma treatment may be improved by targeting A2A receptors. Istradefylline, an FDA-approved drug, shows potential as a novel therapy for glioblastoma (GBM).

Area of Science:

  • Neuro-oncology
  • Pharmacology
  • Cancer Research

Background:

  • Glioblastoma (GBM) is an aggressive brain cancer with limited treatment options and poor prognosis.
  • Adenosine A2A receptor (A2AR) inhibition shows neuroprotective effects and is explored as a cancer therapy.
  • A2AR antagonism presents a potential therapeutic target for GBM.

Purpose of the Study:

  • To investigate A2A receptor inhibition as a potential therapy for glioblastoma.
  • To evaluate Istradefylline (IST) as a feasible agent for A2A receptor blockade in GBM treatment.

Main Methods:

  • Review of existing research on A2A receptor function in cancer and neuroprotection.
  • Analysis of Istradefylline's pharmacological profile and potential antineoplastic properties.
  • Exploration of A2A receptor inhibition as a therapeutic strategy for GBM.

Main Results:

  • A2A receptor inhibition has demonstrated neuroprotective roles in various diseases.
  • Istradefylline, an FDA-approved drug for Parkinson's disease, inhibits A2A receptors.
  • Istradefylline exhibits potential as an antineoplastic agent.

Conclusions:

  • A2A receptor inhibition is a promising therapeutic avenue for glioblastoma.
  • Istradefylline represents a viable drug candidate for targeting A2A receptors in GBM.
  • Further research is warranted to explore IST's efficacy in GBM treatment.
Keywords:
A2A purinoceptorIstradefyllineParkinson’s diseaseadenosineglioblastomaneuroprotectionpurinergic system

More Related Videos

Strategies for Study of Neuroprotection from Cold-preconditioning16:27

Strategies for Study of Neuroprotection from Cold-preconditioning

Published on: September 2, 2010

14.8K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.0K

Related Concept Videos

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.4K
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.1K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
161